The European Medicines Agency, acting through its Committee on Herbal Medicinal Products together with the Pharmacovigilance Risk Assessment Committee, has released a draft reflection paper addressing how safety signals for traditional herbal medicinal products should be identified, assessed, and escalated. According to the agency, public comments will be accepted through October 15, 2026. For any clinic, manufacturer, or consulting partner integrating herbal medicinal products into a portfolio, this is not a background document — it is the piece that closes a structural blind spot in your pharmacovigilance operating model.
The Gap in Your Signal Management Workflow
Your current signal management workflow almost certainly defaults to GVP Module IX as the principal playbook. It is a robust framework. It is also silent on the particularities of herbal medicinal products. That silence is the bottleneck.
The reflection paper exists precisely because EU pharmacovigilance guidance, as it stands today, contains no particular considerations for herbal medicinal products within the relevant signal management modules. Until now, anyone running signal detection on a herbal portfolio has been operating by analogy, adapting small-molecule logic to a categorically different product class. The paper replaces that improvisation with an explicit framework that herbal-focused teams can actually operationalize.
The Document Stack You Must Now Read Together
Stop treating this paper as a standalone reference. It is a companion document. Per EMA, it must be read in conjunction with Directive 2001/83/EC, Regulation (EC) No 726/2004, and Commission Implementing Regulation (EU) No 520/2012, alongside the broader GVP guidance set anchored in EudraLex Volume 9.
If your standard operating procedures for signal detection, validation, analysis, and confirmation do not explicitly accommodate the herbal-specific considerations the paper outlines, your framework is incomplete. Audit it now, before the consultation closes.
Your Action Mandate Before October 15
Treat the public consultation window as a forced exercise in scalability. Three moves, executed in order.
First, map every herbal medicinal product in your portfolio against the reflection paper's scope. Determine whether each product sits within the paper's intended coverage and flag any gaps in your current documentation. Second, pressure-test your signal detection inputs. Whether your sources are spontaneous reports, literature monitoring, or post-authorisation safety studies, confirm they are configured to surface the particular signal types the paper addresses. Third, draft your comment. Whether you are a marketing authorisation holder, a clinic operating with herbal products in your offering, or a consulting partner advising on herbal strategy, your operational reality belongs in the consultation record.
The deadline is not a courtesy. It is the moment the regulator formalizes how "particular" will be defined for the herbal pharmacovigilance framework going forward. Shape that definition now, or inherit one written without your input.